Acura Pharmaceuticals launches combination PSE with anti-meth formulation

PALATINE, Ill. — Acura Pharmaceuticals on Thursday announced the launch of their second pseudoephedrine product, Nexafed Sinus Pressure + Pain (pseudoephedrine HCI 30 mg + acetaminophen 325 mg), a meth-resistant immediate-release tablet that effectively relieves congestion due to colds and allergies, as well as pain and/or fever associated with colds and sinus headaches. 

 

Nexafed Sinus Pressure + Pain will continue to utilize Nexafed's patented Impede technology that disrupts the conversion of PSE into methamphetamine, and will be the first meth-resistant PSE combination sinus medicine available. 

 

"Nexafed Sinus Pressure + Pain gives pharmacists the only meth-resistant combination cold medication with pseudoephedrine on the market," stated Bob Jones, president of Acura Pharmaceuticals. "We are excited to offer pharmacists and consumers a sinus medication with the main ingredient they have relied on to treat their congestion for years combined with acetaminophen to treat pain associated with sinus congestion and pressure, all while fighting meth." 

 

Nexafed is currently available nationwide in drug, mass merchandiser and grocery stores with pharmacies. And in some states like West Virginia, nearly all pharmacies have chosen to replace single ingredient PSE products with meth-resistant products such as Nexafed to counter the impact of meth production felt statewide. 

 

"When NEXAFED replaces traditional, non-meth-resistant PSE products in pharmacies, patients get the same relief they expect, but meth cooks have to look elsewhere for the older products they prefer," Jones said. "This has led to a significant reduction in local meth labs as documented by state and county officials in 2014."